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Our dynamic environment regularly exposes us to potentially life-threatening challenges or stressors. To
answer these challenges and maintain homeostasis, the stress response, an innate coordinated
engagement of central and peripheral neural systems is initiated. Although essential for survival, the
inappropriate initiation of the stress response or its continuation after the stressor is terminated has
pathological consequences that have been linked to diverse neuropsychiatric and medical diseases.
Substantial individual variability exists in the pathological consequences of stressors. A theme of this
Special Issue is that elucidating the basis of individual differences in resilience or its ﬂipside, vulnera-
bility, will greatly advance our ability to prevent and treat stress-related diseases. This can be approached
by studying individual differences in “pro-stress” mediators such as corticosteroids or the hypothalamic
orchestrator of the stress response, corticotropin-releasing factor. More recently, the recognition of
endogenous neuromodulators with “anti-stress” activity that have opposing actions or that restrain
stress-response systems suggests additional bases for individual differences in stress pathology. These
“anti-stress” neuromodulators offer alternative strategies for manipulating the stress response and its
pathological consequences. This review uses the major brain norepinephrine system as a model stress-
response system to demonstrate how co-regulation by opposing pro-stress (corticotropin-releasing
factor) and anti-stress (enkephalin) neuromodulators must be ﬁne-tuned to produce an adaptive
response to stress. The clinical consequences of tipping this ﬁne-tuned balance in the direction of either
the pro- or anti-stress systems are emphasized. Finally, that each system provides multiple points at
which individual differences could confer stress vulnerability or resilience is discussed.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
The stress response is characterized by a synchronized set of
endocrine, immunological, autonomic, behavioral and cognitive
responses to perceived threats that is necessary for survival and has
been conserved throughout evolution. The prevalence of stressors
in the dynamic environment of an animal, make it essential to have
mechanisms that limit activity of stress response systems and
promote rapid recovery to pre-stress levels. For example, activation
of the hypothalamic-pituitary-adrenal (HPA) axis by stress is under
tight feedback regulation that serves to restrain and terminate the
response (Dallman et al., 1972). Dysfunctions in this feedback as aPA, Hypothalamic-pituitary-
ic stress disorder.
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Inc. This is an open access article uresult of repeated or chronic stress or even a single severe stress are
thought to underlie the link between stress and many neuropsy-
chiatric diseases, including depression, post-traumatic stress dis-
order (PTSD), substance abuse and Alzheimer's disease, as well as
medical conditions including obesity, cardiovascular disease, in-
ﬂammatory disorders and irritable bowel syndrome (Chrousos,
2000a; Chrousos and Gold, 1992; de Kloet et al., 2005; Goeders,
2003; McEwen, 1998; Larauche et al., 2012; Chrousos, 2000b;
McEwen and Stellar, 1993). Individual differences in various com-
ponents of glucocorticoid feedback mechanisms are points of po-
tential vulnerability or resilience to stress. For example, variations
in early life maternal care can determine individual sensitivity of
this feedback through epigenetic mechanisms that determine
glucocorticoid receptor expression (Weaver et al., 2004).
Although feedback inhibition of the HPA axis by glucocorticoids
is critical in restraining the endocrine limb of the stress response,
neural circuits underlying other limbs of the stress response are not
similarly regulated. For example, whereas glucocorticoids inhibit
corticotropin-releasing factor (CRF) mRNA expression in neurons ofnder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Fig. 1. Schematic depicting the relationship between phasic and high tonic LC activity.
Shown are representative peri-stimulus time histograms (PSTHs) of LC neuronal ac-
tivity during a trial of repeated auditory stimulation occurring at the arrowhead. In the
phasic mode LC neurons are more responsive to sensory stimuli and ﬁre with a burst of
spikes followed by a period of inhibition before activity returns to pre-stimulus fre-
quency. In the high tonic mode, LC neurons ﬁre faster throughout the trial of sensory
stimulation and show little response to the sensory stimuli. These histograms were
generated before (PHASIC) and after (HIGH TONIC) CRF administration. Exposure of LC
neurons to CRF or exposure of animals to acute stress biases LC activity towards the
high tonic mode that is associated with increased arousal, scanning attention and
behavioral ﬂexibility. Activating MOR in the LC as occurs during stress recovery biases
discharge towards lower tonic and increased phasic activity and this is associated with
focused attention and maintenance of ongoing behavior.
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tuitary adrenocorticotropin release, they increase CRF mRNA in
neurons of the amygdala and bed nucleus of the stria terminalis
that are thought to underlie behavioral aspects of the stress
response (Makino et al., 1994a, 1994b). Given the complexity of
stress circuitry, there are likely to be multiple mechanisms for
counter-regulation of different components of the stress response.
Identifying these mechanisms can guide strategies to prevent or
treat stress-related neuropsychiatric diseases. Mechanisms for
counteracting stress are also potential points at which individual
differences can be expressed and thus can be determinants of stress
vulnerability and/or resilience.
One mechanism for counteracting stress responses is through
stress-elicited engagement of neuromodulators that act in oppo-
sition to “pro-stress” systems or neuromediators. Some neuro-
mediators that have been characterized as opposing stress include
neuropeptide Y, endocannabinoids, urocortins and endogenous
opioids (Bowers et al., 2012; Crowe et al., 2014; Gunduz-Cinar et al.,
2013; Heilig and Thorsell, 2002; Hillard, 2014; Kozicz, 2007; Reul
and Holsboer, 2002).
This review presents the locus coeruleus (LC)-norepinephrine
(NE) system as a model stress-response system that is co-regulated
by the opposing inﬂuences of the pro-stress mediator, CRF and the
opioid neuropeptide, enkephalin during acute stress. We begin
with a brief description of the anatomical and physiological char-
acteristics of the LC-NE systemwith respect to its role in behavioral
and cognitive aspects of the stress response (additional detail on
anatomical and physiological characteristics of the LC-NE system
are reviewed in (Aston-Jones et al., 1995)). This is followed by a
discussion of CRF as the orchestrator of the stress response and a
neurotransmitter that activates the LC-NE system in response to
stress. Endogenous opioids are introduced as “anti-stress” media-
tors that co-regulate the LC in a manner that opposes CRF. The
adaptive nature of maintaining a balance between CRF and
endogenous opioid inﬂuences in the LC is emphasized. Individual
factors that can tip this balance to result in pathology or determine
vulnerability are discussed. An underlying theme is that systems
that oppose the stress response, while protective, can also be the
basis for alternate pathologies.
2. The locus coeruleus and stress
The following section reviews anatomical and physiological
characteristics of the LC-NE system that have implicated the system
in stress. More detailed information about this system and its other
putative functions that are outside the scope of this review can be
found in (Aston-Jones et al., 1995; Foote et al., 1983; Berridge and
Waterhouse, 2003). The LC is a compact cluster of NE neurons in
the pons that serves as the primary source of brain NE (Grzanna and
Molliver, 1980). A distinguishing anatomical feature of the LC is its
widespread, highly collateralized projection system that innervates
the entire neuraxis (Aston-Jones et al., 1995; Swanson and
Hartman, 1976). Through this axonal system the nucleus LC can
broadly inﬂuence neuronal activity throughout the brain. Notably,
the LC serves as the primary source of NE in forebrain regions such
as the hippocampus and cortex that govern cognition, memory and
complex behaviors.
The physiological characteristics of LC neurons have been
studied in vivo in rodents and non-human primates and in vitro in
slice preparations and have implicated this system in arousal,
attention and behavioral ﬂexibility (Aston-Jones and Bloom, 1981a,
1981b; Foote et al., 1980; Williams and Marshall, 1987; Aston-Jones
and Cohen, 2005). LC neurons discharge spontaneously and their
tonic rate is positively correlated to arousal state (Aston-Jones and
Bloom, 1981b; Foote et al., 1980). However, the relationshipbetween neuronal activity and arousal is more than just correlation
because selective activation or inhibition of LC neurons results in
cortical and hippocampal electroencephalographic (EEG) activation
or inhibition, respectively, indicating causality between LC
discharge rate and arousal (Berridge and Foote,1991; Berridge et al.,
1993). As described below, LC activation is necessary for cortical
EEG activation by stress (Page et al., 1993).
In addition to spontaneous ﬁring, LC neurons are phasically
activated by salient, multimodal stimuli that elicit a burst of
discharge followed by a period of inhibition (e.g., Fig. 1) (Aston-
Jones and Bloom, 1981a), (Aston-Jones and Bloom, 1981a; Foote et
al., 1980). The phasic response precedes orientation to the elicit-
ing stimuli, suggesting that the LC-NE system redirects attention
towards salient sensory stimuli. LC neurons are thought to
discharge synchronously during phasic activation as a result of
electrotonic coupling through gap junctions between dendrites
outside of the nucleus, in the peri-coerulear (peri-LC) region
(Ishimatsu and Williams, 1996). In contrast, during spontaneous or
tonic LC discharge, the neurons are thought to be uncoupled (Usher
et al., 1999). When LC neurons are discharging at a relatively high
spontaneous rate (high tonic mode), phasic LC activation by stimuli
is greatly attenuated so that high tonic discharge precludes phasic
activity (Valentino and Aulisi, 1987).
LC neurons switch between phasic and high tonic discharge
modes to bias behavior differently and these shifts facilitate
adaptation in a dynamic environment (Fig. 1) (see for reviews
(Aston-Jones and Cohen, 2005; Bouret and Sara, 2005)). LC
neuronal recordings in monkeys performing operant tasks suggest
that phasic LC discharge is associated with focused attention and
staying on-task whereas high tonic discharge is associated with
labile attention and going off-task (Usher et al., 1999; Rajkowski
et al., 1994). A shift from phasic to high tonic LC discharge has
been suggested to promote behavioral ﬂexibility, disengaging ani-
mals from attention to speciﬁc stimuli and ongoing behaviors and
favoring scanning the environment for stimuli that promote alter-
nate, more rewarding behaviors (Aston-Jones and Cohen, 2005).
The ability to shift between phasic and tonic ﬁring modes would
promote rapid adjustments in response to a stressor or after
stressor termination (Fig. 1).
Convergent lines of evidence suggest that stressors that initiate
the HPA response to stress also activate the LC-NE system and the
parallel engagement of these two systems serves to coordinate
endocrine and cognitive limbs of the stress response (Valentino and
R.J. Valentino, E. Van Bockstaele / Neurobiology of Stress 1 (2015) 23e32 25Van Bockstaele, 2008). This has been studied using different
stressors including shock, auditory stress, immunological stress,
autonomic stressors, restraint and social stress and different end-
points including NE turnover, NE release, LC neuronal activity, c-fos
expression or tyrosine hydroxylase expression (Cassens et al., 1981,
1980; Korf et al., 1973; Thierry et al., 1968; Beck and Fibiger, 1995;
Bonaz and Tache, 1994; Britton et al., 1992; Campeau and Watson,
1997; Chan and Sawchenko, 1995; Chang et al., 2000; Curtis et al.,
2012; Dun et al., 1995; Duncan et al., 1993; Funk and Amir, 2000;
Graham et al., 1995; Ishida et al., 2002; Kollack-Walker et al.,
1997; Lacosta et al., 2000; Makino et al., 2002; Rusnak et al., 2001;
Sabban and Kvetnansky, 2001; Smagin et al., 1994; Smith et al.,
1992, 1991; Valentino et al., 1991).
In response to acute stress LC spontaneous discharge increases
and this is temporally correlated to cortical EEG activation indica-
tive of arousal (Curtis et al., 2012; Lechner et al., 1997; Page et al.,
1992). Moreover, LC activation is necessary for forebrain EEG acti-
vation by stress because selective bilateral inactivation of LC neu-
rons with clonidine microinfusions prevents this response (Page
et al., 1992). As LC spontaneous discharge rate increases, re-
sponses to discrete sensory stimuli are attenuated (Curtis et al.,
2012; Valentino and Wehby, 1988a). Thus, acute stressors bias LC
discharge towards a high tonic mode that would facilitate disen-
gagement from ongoing tasks, scanning attention and behavioral
ﬂexibility, all of which would be adaptive in coping with an im-
mediate threat (Fig. 2A). Notably, in the absence of stress, high tonic
LC activity would not be adaptive and would translate to hyper-
arousal and an inability to concentrate or to maintain performance
on tasks that require focused attention. These are characteristic
symptoms of stress-related psychiatric disorders such as PTSD and
major depression, both of which also show evidence of LC-NE hy-
peractivity (Southwick et al., 1999; Wong et al., 2000).
3. Corticotropin-releasing factor, the locus coeruleus and
stress
Substantial evidence now implicates the stress-related neuro-
peptide, CRF as a primary mediator of stress-induced LC activation.
CRF was initially characterized as the paraventricular hypothalamic
neurohormone that initiates anterior pituitary adrenocorticotropin
secretion in response to stressors (Vale et al., 1981). This discovery
inspired a body of research from diverse laboratories that ulti-
mately provided convergent evidence for a parallel function of CRF
as a brain neuromodulator that coordinates autonomic, behavioral
and cognitive responses to stress with the endocrine limb (See forFig. 2. Schematic depicting the net effect of different conditions on LC activity and associat
(yellow cell) afferents to the LC are engaged. The net effect is a shift of LC activity toward
behavioral ﬂexibility. Endogenous opioids act as a restraint and facilitate recovery of neuron
CRF inﬂuence is attenuated because CRF1 internalizes and the opioid effect predominates. In
susceptible to opioid abuse. C) A decreased opioid inﬂuence as would occur with toleranc
enduring. The enhanced arousal-like state could account for symptoms of PTSD and depre
referred to the web version of this article.)Review (Bale and Vale, 2004; Owens and Nemeroff, 1991)). CRF-
containing axon terminals and CRF receptors were regionally
localized in brain areas that regulate autonomic functions,
emotional expression and cognition (Sakanaka et al., 1987;
Swanson et al., 1983). Central CRF administration was demon-
strated to mimic many of the autonomic and behavioral aspects of
the stress response even in hypophysectomized rats (Britton et al.,
1982; Brown and Fisher, 1985; Brown et al., 1982; Tache et al., 1983;
Tache and Gunion, 1985; Cole and Koob, 1988; Snyder et al., 2012;
Heinrichs et al., 1995; Koob and Heinrichs, 1999; Sutton et al.,
1982; Swerdlow et al., 1986). The most convincing evidence that
CRF serves as the major molecule that organizes the different
components of the stress response came from the numerous
studies demonstrating that stress-elicited effects are prevented or
reversed by central administration of CRF antagonists or are absent
in animals with genetic deletions of CRF receptors (Reul and
Holsboer, 2002; Contarino et al., 1999; Lenz et al., 1988;
Kawahara et al., 2000; Heinrichs et al., 1992; Korte et al., 1994;
Smagin et al., 1996; Tazi et al., 1987; Martinez et al., 1997; Bueno
and Gue, 1988; Gutman et al., 2003; Keck et al., 2004; Muller
et al., 2004). Together, the ﬁndings led to the compelling notion
that coordinated CRF release in speciﬁc neural circuits integrates
the different limbs of the stress response. Although the autonomic
and behavioral processes initiated by CRF are adaptive in
responding to life-threatening challenges, if they were engaged in
the absence of such a challenge or if they persisted long after the
challenge was terminated this would be considered pathological.
Consistent with this, many stress-related disorders including
depression, PTSD and irritable bowel syndrome have been attrib-
uted to excessive CRF that is not counterregulated (Larauche et al.,
2012; Bremner et al., 1997; Gold and Chrousos, 2002; Tache et al.,
1993).
Multiple CRF receptors have been identiﬁed, with the CRF1
subtype being the most predominant in brain and the subtype
considered to be responsible formost effects attributed to the stress
response, although some rodent models of anxiety and depression
also implicate a role for CRF2 (Dautzenberg and Hauger, 2002;
Hauger et al., 2009; Maier and Watkins, 2005; Risbrough et al.,
2009, 2004). For the purpose of this review, the CRF effects dis-
cussed will be those mediated by CRF1 unless otherwise noted.
The LC-NE system is a target of CRF neurotransmission. CRF-
immunoreactive axon terminals synaptically contact LC dendrites,
particularly those that extend into the peri-LC (Tjoumakaris et al.,
2003; Van Bockstaele et al., 1996). The majority of these synapses
are asymmetric or excitatory-type and approximately one third co-ed cognitive effects. A) During acute stress both CRF (red cell) and endogenous opioid
s high tonic activity that is associated with increased arousal, scanning attention and
al activity to pre-stress levels after the stress is terminated. B) With repeated stress, the
this condition, the cells are in a mild state of opioid dependence and individuals may be
e would enhance the neuronal and cognitive effects of CRF and these would be more
ssion. (For interpretation of the references to color in this ﬁgure legend, the reader is
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2001). Additionally, CRF axon terminals are apposed to non-labeled
axon terminals that synapse with LC dendrites suggesting that CRF
can affect LC neuronal activity through both direct and indirect
effects. CRF afferents to LC dendrites in the peri-LC derive from the
central amygdalar nucleus (CeA) and the paraventricular hypo-
thalamic nucleus (Reyes et al., 2005; Valentino et al., 1992; Van
Bockstaele et al., 1998; Van Bockstaele et al., 1999), whereas those
to the nuclear LC include the nucleus paragigantocellularis, Bar-
rington's nucleus and the paraventricular hypothalamic nucleus
(Reyes et al., 2005; Valentino et al., 1992, 1996). Hypothalamic CRF
neurons that project to the LC are a distinct population from those
that project to the median eminence to regulate adrenocortico-
tropin release (Reyes et al., 2005).
In slice preparations in vitro, CRF increases LC discharge rates in
the presence of tetrodotoxin or cadmium, suggesting that these are
direct effects on LC neurons (Jedema and Grace, 2004). These ac-
tions are mediated by CRF1 Gs-protein coupled receptors, are cyclic
AMP dependent and are mediated by a decreased potassium
conductance (Jedema and Grace, 2004; Schulz et al., 1996). In vivo,
CRF mimics the effects of stressors on LC neuronal activity when
administered intracerebroventricularly or directly into the LC. Thus,
CRF increases LC spontaneous discharge rate and attenuates
sensory-evoked phasic discharge, thereby shifting discharge to a
high tonic mode that would promote increased arousal, going off-
task, scanning the environment and behavioral ﬂexibility (Curtis
et al., 1997; Valentino and Foote, 1987; Valentino et al., 1983).
Consistent with this, bilateral intra-LC CRF injections activate
forebrain EEG activity (Curtis et al., 1997), behavioral arousal (Butler
et al., 1990) and enhance behavioral ﬂexibility in a rat attention set
shifting task (Snyder et al., 2012). The increased CRF-elicited LC
neuronal activation also translates to elevated forebrain NE release
(Page and Abercrombie, 1999).
LC neurons are not under tonic CRF regulation because CRF
antagonists typically do not affect LC discharge rate (Curtis et al.,
1994). Rather, CRF is released in the LC by acute stressors to shift
the mode of activity to a high tonic state. This is evidenced by the
ability of local microinfusions of CRF antagonists into the LC to
prevent LC activation elicited by the acute stressors, hypotension
and colonic distention (Page et al., 1993; Valentino et al., 1991;
Lechner et al., 1997). Central administration of CRF antagonists
also prevented LC activation by acute exposure to predator odor,
which also shifts the mode of LC discharge to a high tonic state
(Curtis et al., 2012). Other endpoints of stress-induced LC activation,
such as forebrain NE release and cortical EEG activation are also
prevented by intra-LC microinfusion of CRF antagonists (Page et al.,
1993; Kawahara et al., 2000). Together, these studies support a
model whereby acute stress engages CRF inputs to the LC to bias
activity towards a high tonic state that would favor increased
arousal, scanning attention and behavioral ﬂexibility (Fig. 2A).
Studies combining retrograde tracing from the LC and immuno-
histochemistry to localize CRF and the immediate early gene, c-fos
implicate the central nucleus of the amygdala and Barrington's
nucleus as sources of CRF that activate the LC during hypotensive
stress and colonic distention, respectively and suggest that CRF
circuits activating the LC are stressor-speciﬁc (Curtis et al., 2002;
Rouzade-Dominguez et al., 2001). Similar functional neuro-
anatomy approaches may be used to delineate the CRF-related
circuitry underlying LC activation by psychogenic stressors that
are more common in humans.
4. Endogenous opioids: counteracting stress
Endogenous opioids have long been implicated in the stress
response based on evidence for their release by stressors and theirability to either attenuate or mimic stress responses depending on
the speciﬁc opioid receptor that is activated. Several laboratories
were involved in the discovery and characterization of the endog-
enous “morphine-like” peptides and their receptors in the early
1970's (Goldstein et al., 1979; Hughes et al., 1975; Ling et al., 1976;
Bradbury et al., 1976; Meunier et al., 1995; Pert and Snyder, 1973).
Distinct genes were identiﬁed that encode for the precursors of the
three major endogenous opioid peptide families, pre-
proopiomelanocortin, preproenkephalin and preprodynorphin
(Meunier et al., 1995; Comb et al., 1982; Kakidani et al., 1982;
Nakanishi et al., 1979; Noda et al., 1982; Nothacker et al., 1996;
Pan et al., 1996). The active peptides cleaved from these pre-
cursors, endorphin, enkephalin and dynorphin, produce their ef-
fects through actions on m-, d and k- G-protein coupled receptors,
respectively (Mogil and Pasternak, 2001; Pasternak, 2004).
Opioids are best recognized for their ability to blunt pain.
However, this may be an expression of a broader function to
counter stress. Pain can be considered a stressor because it signals
physical threat and it elicits many of the same responses as non-
noxious stressors, including increased arousal, changes in auto-
nomic activity, avoidance behaviors and negative affect (Ribeiro
et al., 2005). Although opioid analgesia attenuates the sensory as-
pects of pain, a major component of the analgesic response involves
a blunting of the negative affective component of pain (Zubieta
et al., 2001). An “anti-stress” activity of endogenous opioids may
be speciﬁcally mediated by the m-opioid receptor (MOR), the re-
ceptor that shows greater selectivity for b-endorphin, endomor-
phin and the enkephalins (Akil et al., 1984; Sora et al., 1997; Drolet
et al., 2001). In contrast, a stress-like aversion has been associated
with the dynorphin-k-opioid receptor system (Chavkin, 2013).
Support for an anti-stress function of endogenous opioids comes
from studies showing evidence for stress-elicited opioid release. In
animal studies, many stressors, including those that are non-
noxious, produce an analgesia that is cross tolerant with
morphine and is antagonized by naloxone (Girardot and Holloway,
1984; Lewis et al., 1980; Miczek et al., 1982; Rodgers and Randall,
1985). This is also apparent in humans. For example, the presen-
tation of combat-related stimuli to PTSD patients produces
naloxone-sensitive analgesic responses (Pitman et al., 1990; van der
Kolk et al., 1989). Stress also increases preproenkephalin mRNA in
certain brain regions and b-endorphin in plasma (Ceccatelli and
Orazzo, 1993; Dumont et al., 2000; Mansi et al., 2000; Lightman
and Young, 1987; Rossier et al., 1977).
One mechanism by which endogenous opioids can counteract
stress is through actions that oppose those of CRF. Enkephalin and
CRF are co-localized in many hypothalamic neurons, in the medial
preoptic nucleus and in the bed nucleus of the stria terminalis
(Sakanaka et al., 1989). The cellular targets of these neurons are
potential sites of interaction between CRF and enkephalin. Addi-
tionally, CRF and enkephalin distribution overlaps in brain regions
underlying behavioral and autonomic components of the stress
response including the CEA, parabrachial nucleus and nucleus
tractus solitarias (Swanson et al., 1983; Drolet et al., 2001; Sakanaka
et al., 1989). That these neuromodulators act in an organized
fashion to ﬁne-tune neuronal activity in response to stressors is
particularly evident in their co-regulation of the LC-NE system
during stress (Valentino and Van Bockstaele, 2001).
5. CRF and opioid co-regulation of the locus coeruleus during
acute stress
LC neurons are anatomically poised for co-regulation by CRF and
enkephalin. Although few axon terminals in the LC and peri-LC
region co-localize CRF and enkephalin, LC dendrites receive
convergent input from CRF- and enkephalin-containing axon
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Xu et al., 2004). Enkephalin innervation of the LC derives from
rostral medullary nuclei including the nucleus para-
gigantocellularis and nucleus prepositus hypoglossi (Drolet et al.,
1992). Lesions of the central nucleus of the amygdala that sub-
stantially diminish CRF innervation of the LC and peri-LC region
have little effect on enkephalin innervation of the LC (Tjoumakaris
et al., 2003). Moreover, few (2%) LC-projecting paraventricular hy-
pothalamic nucleus neurons are enkephalin-containing, whereas
30% are immunoreactive for CRF (Reyes et al., 2005). Together these
ﬁndings suggest that enkephalin and CRF axon terminals that
converge onto LC neurons derive from different sources.
Opioids acting at MOR on LC neurons have effects that are
directly opposite to those of CRF1 activation. MOR activation in-
hibits the formation of cyclic AMP and hyperpolarizes LC neurons
through an increase in potassium conductance (Williams and
North, 1984; Aghajanian and Wang, 1987). In vivo MOR agonists
bias LC activity towards a phasic mode, increasing synchrony and
decreasing tonic discharge rate without changing or slightly
increasing phasic evoked responses (Valentino and Wehby, 1988b;
Zhu and Zhou, 2001). Like CRF, opioids do not tonically regulate LC
activity because neither MOR antagonists nor k-opioid antagonists
affect LC activity of unstressed rats (Chaijale et al., 2013; Curtis et al.,
2001; Kreibich et al., 2008).
The initial evidence for stress-induced opioid regulation of LC
activity came from the demonstration that systemic administration
of the opioid antagonist, naloxone increased LC discharge rates of
cats undergoing restraint stress, but not control cats (Abercrombie
and Jacobs,1988). Later studies using exposure to predator odor as a
stress, provided evidence for CRF and enkephalin co-release during
stress (Curtis et al., 2012). During this stress LC neurons shifted
from a phasic to a high tonic mode, such that spontaneous
discharge increased and LC and auditory-evoked discharge
decreased. Administration of a CRF antagonist prior to the stress
changed this response to a large inhibition of tonic activity with
slightly increased auditory-evoked activity, reminiscent of the ef-
fects of morphine administration and this was prevented by prior
naloxone administration. Thus, in the presence of a CRF antagonist,
exposure to the stressor unmasked an opioid inhibition, suggesting
that both CRF and enkephalin were co-released during the stress to
regulate LC discharge rate. Notably, removal of both the CRF and
opioid inﬂuence in the LC by prior administration of both a CRF
antagonist and naloxone rendered these neurons completely un-
responsive to stressors suggesting that these afferents are the pri-
mary regulators of LC activity during acute stress (Curtis et al.,
2012). CRF and opioid regulation of LC activity was also demon-
strated during a physiological stressor, hypotensive stress, although
the temporal aspects of opioid release during this stress were less
clear (Valentino et al., 1991; Curtis et al., 2001). During hypotensive
stress, LC discharge rate increased and when the stressor was
terminated and blood pressure returned to baseline LC discharge
was robustly inhibited for several minutes (Valentino and Wehby,
1988a; Curtis et al., 2001). Intra-LC administration of a CRF antag-
onist during the stress prevented the stress-induced excitation and
revealed a greater post-stress inhibition that is naloxone-sensitive
(Valentino and Wehby, 1988a; Curtis et al., 2001). Additionally, LC
administration of naloxone alone increased the time taken for LC
excitation to recover to pre-stress levels. This study suggested that
opioid inhibition was important in recovery of LC activity from this
physiological stressor.
Together these ﬁndings support a model whereby acute
stressors engage both CRF and opioid inputs to the LC (Fig. 2A). CRF
is the predominant afferent and shifts LC discharge to a high tonic
mode that favors increased arousal, scanning attention and
behavioral ﬂexibility, effects that would be adaptive copingresponses to an acute threat. At the same time endogenous opioid
afferents that have opposing actions are engaged. These function to
restrain the CRF excitation and to promote recovery after stressor
termination. These CRF/opioid interactions adjust the activity and
reactivity of LC neurons so that level of arousal and processing of
sensory stimuli are optimized to facilitate adaptive behavioral re-
sponses to stressors. The protective effects of opioids are apparent
in the many studies documenting that morphine administration
shortly after a single traumatic event reduces the incidence of PTSD
(Bryant et al., 2009; Holbrook et al., 2010).
6. Repeated stress tips the balance towards opioid regulation
During acute stress MOR regulation of the LC serves as an
adaptive counterbalance that curbs the excitatory effects of CRF and
protects against the consequences of a hyperactive brain norepi-
nephrine system. However, tipping the balance in favor of a MOR
inﬂuence incurs alternative costs (Fig. 2B). Like the CRF response to
stress, the opposing opioid response must be limited. The persis-
tence of an opioid inﬂuence can produce enduring modiﬁcations in
neural circuits that result in opioid tolerance and dependence.
Indeed, this may be an underlying basis for the association between
stress and substance abuse.
A bias toward opioid regulation of the LC was recently demon-
strated to occur with repeated social stress, which diminishes CRF
function and enhances MOR function in the LC (Chaijale et al.,
2013). Unlike acute stressors, repeated social stress decreased LC
neuronal discharge rate by 48 h after the last stress and this inhi-
bition was naloxone-sensitive indicating that MOR receptors were
occupied. Analysis of CRF1 and MOR protein levels and receptor
trafﬁcking in the LC demonstrated that this paradoxical stress-
induced inhibition is due to both a loss of CRF-elicited excitation
as a result of CRF1 internalization and to increased opioid release
and MOR signalling (Chaijale et al., 2013). Importantly, the
magnitude of the naloxone-elicited LC excitation was greater than
that which could be explained by reversal alone and was similar to
that observed with naloxone administration to morphine-
dependent rats (Valentino and Wehby, 1989). By 10 days after the
last social stress, LC neurons were not inhibited and naloxone
produced an even greater activation suggesting that the neurons
were opioid tolerant and dependent. Notably, naloxone adminis-
tration to rats exposed to repeated social stress was also associated
with mild signs of physical opioid withdrawal. These ﬁndings were
consistent with previous reports that repeated social stress in mice
results in analgesia that is cross tolerant with morphine and in
opioid dependence as determined by naloxone precipitated with-
drawal signs (Miczek et al., 1986; Miczek, 1991). Together the re-
sults suggest that repeated social stress shifts the balance of LC
activity towards inhibitory opioid regulation by engaging endoge-
nous opioid afferents to the LC and by downregulating CRF re-
ceptors. The opioid imbalance in the LC produced by repeated social
stress may generalize to other stressors. For example, in an animal
model of PTSD that involves exposure to three different severe
stressors (the single prolonged stress model) LC neurons were also
paradoxically inhibited (George et al., 2013). For both of these stress
models the temporal aspects of opioid release in the LC have yet to
be determined and it is not clear whether there is concurrent
release of both peptides, or whether opioids are released at a later
time.
Thus, in contrast to acute stress, where CRF excitation pre-
dominates and opioids act to temper this response and promote
recovery, with repeated stress the inﬂuence of CRF is diminished
and the balance is tipped in favor of opioid regulation (Fig. 2B).
Although this protects against the negative consequences of a
hypernoradrenergic state, it comes with its own cost. The
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individuals tolerant to opioid analgesia and vulnerable to opioid
abuse in an effort to avoid negative effects associated with mild
withdrawal. These effects are clinically relevant with respect to
PTSD. Individuals with PTSD are tolerant to opioid analgesics and in
general have a higher use of analgesics (Schwartz et al., 2006;
Jacobsen et al., 2001; Fareed et al., 2013). Importantly substantial
co-morbidity exists between PTSD and opioid abuse (Schwartz
et al., 2006; Fareed et al., 2013b; Mills et al., 2007; Clark et al.,
2001). At the basis of this comorbidity may lie an over responsive
opioid system that was initially engaged to counteract responses to
trauma. This is an example of stress-related pathology arising from
a dysfunction in a system designed to oppose stress.
7. Chronic opioid administration tips the balance towards
CRF regulation
In contrast to the consequences of repeated stress, conditions
that decrease the opioid inﬂuence in the LC would bias regulation
towards CRF-mediated excitation by removing restraint on the CRF
system and hindering recovery of neuronal activity after stress
termination (Fig. 2C). This would be expressed as an exaggerated
and more enduring activation of the LC-NE system that would
translate to exaggerated hyperarousal that is characteristic of PTSD
and other stress-related psychiatric disorders. A decrease in opioid
inﬂuence could occur in individuals who become opioid tolerant as
a result of chronic medical use or abuse. Consistent with this, in rats
chronically treated with morphine, LC neurons respond with a
greater excitation to hypotensive stress (Xu et al., 2004). This is due
in part to sensitization of LC neurons to CRF because the CRF dose-
response curve for LC activation is shifted to the left and has a
greater maximum response in these animals. Importantly,
enhanced LC sensitivity to CRF in rats chronically treated with
morphine translated to exaggerated stress-induced behavioral
activation (Xu et al., 2004). For example, morphine-treated rats
exposed to swim stress show excessive climbing behavior (Xu et al.,
2004), a response that has been linked to brain NE (Detke et al.,
1995) and that is similar to the effects of CRF injected locally into
the LC (Butler et al., 1990).
These basic studies imply that chronic opioid administration by
humans can sensitize the LC-NE arousal system to stressors and this
can also be a basis for comorbidity of opioid abuse and PTSD.
However, in contrast to repeated stress, where the stress leads to
adaptive mechanisms that predispose to opioid abuse, here opioid
abusewould be responsible for a predisposition to the hyperarousal
symptoms of PTSD. Either case could account for the high comor-
bidity of opioid abuse and PTSD (Fareed et al., 2013b; Clark et al.,
2001).
8. Individual differences in opioid regulation of the LC:
potential determinants of resilience
Given the role of opioids in buffering LC-NE activation during
stress and the pathological implications of excessive or insufﬁcient
opioid inﬂuence described above, individual differences in either
enkephalin expression or MOR sensitivity are potential de-
terminants of stress resilience/vulnerability or the form of pathol-
ogy that is expressed. For example, whereas decreased MOR
function may predispose to hyperarousal symptoms of stress-
related disorders because of a decreased ability to counteract CRF
effects, it may protect against substance abuse because the neurons
won't become opioid-dependent. In contrast, individuals with
greater MOR sensitivity would be predicted to be protected from
hyperarousal symptoms but more prone to substance abuse. Thus,
how the balance is tipped will determine how the stress-relatedpathology is expressed. In this regard MOR density, sensitivity
and trafﬁcking, as well as enkephalin expression are affected by sex
and hormonal status (Torres-Reveron et al., 2008, 2009; Van
Kempen et al., 2013; Milner et al., 2013; Craft, 2008). The re-
lationships are not clear-cut and may be dependent on the species,
the endpoint and brain region studied. Nonetheless, studies doc-
umenting decreased MOR sensitivity in females (Kepler et al., 1991;
Ji et al., 2006; Wang et al., 2006) would be consistent with reports
that stress-related diseases characterized by hyperarousal are more
prevalent in females whereas substance abuse is more prevalent in
males (Kessler et al., 2005, 1994; Breslau, 2002).
Like sex, age is a potential determinant of individual resilience/
vulnerability. Developmental differences in enkephalin innervation
of the LC or MOR expression by LC neurons will determine the
balance of CRF-opioid regulation of the LC-NE system at different
ages and can contribute to age-related determinants of stress
vulnerability. Although developmental differences in the
enkephalin-MOR system that regulates the LC have not speciﬁcally
been investigated, differences in enkephalin expression and MOR
signalling have been reported in other brain regions during post-
natal development (Kwok et al., 2014). Preliminary ﬁndings in our
laboratory suggest that LC neurons of adolescent male rats (42e47
day old) are activated by social stress to a similar magnitude as seen
in adults but do not recover as well, suggesting that the opioid
system is not completely developed and this may increase
vulnerability to the hyperarousal components of stress-related
pathology.
Another potential determinant of individual variability lies in
the MOR gene. A single nucleotide polymorphism (SNP) A118G
occurring in exon 1 of the MOR gene is relatively common in in-
dividuals of European ancestry (15e30%) and Asian ancestry
(40e50%) (Kwok et al., 2014). Individuals with the G118 allele
exhibit less sensitivity to morphine analgesia and in vitro studies
suggest that this SNP confers a loss of function although this is not a
uniform ﬁnding of all studies (Mague and Blendy, 2010). For
example, HPA inhibition is greater in animals with this SNP, sug-
gesting increased opioid inhibitory tone. Notably, there is evidence
for an interaction of this SNP with sex in certain endpoints (Mague
et al., 2009). Elucidating the impact of this MOR SNP on LC re-
sponses to stressors may identify this as a genetic source of vari-
ability that interacts with sex to determine resilience/vulnerability
to stress.9. Conclusions
Stress-related pathology is generally thought to result from a
dysfunction in the mediators of the stress response as a conse-
quence of repeated or chronic stress. This review introduced the
concept that a dysfunction of systems that are engaged during
stress but are designed to restrain the stress response produce
alternate pathological consequences. Although this review focused
on the LC as a target for opposing opioid/CRF interactions, there are
other potential points of opioid/CRF convergence in brain at which
an altered balance between the systems could result in pathology.
Thus far, the preponderance of evidence points to CRF1-MOR in-
teractions in the serotonergic dorsal raphe nucleus (DRN) as being
somewhat analogous to the interactions in the LC (Staub et al.,
2012). CRF1 and MOR have opposing effects on GABA neurons in
the DRN, with CRF1 activating GABA and indirectly inhibiting 5-HT-
DRN neurons and MOR inhibiting GABA neurons and indirectly
exciting 5-HT-DRN neurons (Kirby et al., 2000, 2008; Jolas and
Aghajanian, 1997). Similar to the effects on LC neurons described
above, chronic morphine sensitizes DRN-5-HT neurons to CRF and
that has been proposed to underlie vulnerability to stress-induced
R.J. Valentino, E. Van Bockstaele / Neurobiology of Stress 1 (2015) 23e32 29relapse (Staub et al., 2012). Notably, these studies used male
subjects.
In addition to opioids, there are other endogenous neuro-
mediators that are proposed to protect against the effects of stress.
Innate individual differences in endogenous mechanisms that
oppose the stress response can determine vulnerability/resilience
to the pathological consequences of stress. Likewise, sex differences
or age differences in stress-opposing systems are potential con-
tributors to sex differences or developmental differences in stress
vulnerability, respectively. Identifying and characterizing the
stress-opposing neuromediators such as the endogenous opioids
and their circuitry would be a major advance in approaching the
treatment of stress-related disorders.Acknowledgments
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